Reata Pharma (RETA) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharmaceuticals, Inc. Announces Third Quarter 2016 Financial and Operating Results
November 14, 2016 8:30 AM ESTIRVING, Texas, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs.
Financial Highlights
The Company incurred operating expenses of $13.5 million for the quarter ended September 30, 2016, with research and development accounting for $9.3 million. This compares to operating expenses of $12.0 million for the same period of the year prior, when research and development accounted for $8.6 million. ... More
